Pharmacodynamic Effects of Litifilimab in Lupus in a Randomized, Placebo-Controlled Phase 2 Study: Rapid and Sustained Reductions in Type I Interferon-Associated Gene Expression and Cytokines.

At week 24 in the litifilimab 450 mg group, analyses showed a trend toward greater median IFNα reductions among SRI‐4 responders compared with nonresponders (Figure 2 ), suggesting a possible association between IFNα reduction and SRI‐4 response.

also in 53,322 other papers